Opko Health, Inc. OPK

What this company does

OPKO Health manages its operations in two reportable segments, diagnostics and pharmaceuticals, with the pharmaceutical segment consisting of pharmaceutical operations in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France and the United States, and its global pharmaceutical research and development operations, and the diagnostics segment consisting primarily of the clinical laboratory operations of BioReference. As of December 31, 2025, it had 2,275 full-time employees worldwide. It operates established, revenue-generating pharmaceutical platforms in Spain, Ireland, Chile and Mexico. Through its pharmaceutical business, it manufactures and sells Rayaldee, an FDA-approved treatment for secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease and vitamin D insufficiency. BioReference continues to operate its core clinical and women's health testing business in the New York and New Jersey regions and maintains its national specialty urology franchise, including the 4Kscore prostate cancer test. The company was originally incorporated in Delaware in October 1991 under the name Cytoclonal Pharmaceutics, Inc., which was later changed to eXegenics, Inc., and on June 8, 2007 it changed its name to OPKO Health, Inc.

Written from the business description in OPKO Health, Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 26 February 2026. Every sentence was checked against that document before publication.